Personalized vaccines such as MVX-ONCO-1 use autologous tumor cells to present a full antigen repertoire, while engineered fusion proteins such as CUE-101 demonstrate durability in HPV16+ HLA-A*02:01-restricted disease (mOS 24.4 months) [154,164]. Here, HLA-A is linked to neoplasm.